BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE